Press Release : Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million

 
   NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, 
AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD 
BE UNLAWFUL 
 
   Basel, Switzerland, February 24, 2021 
 
   Basilea Pharmaceutica Ltd. ("Basilea" or the "Company") announced today 
that it has successfully placed 1 million new shares in a private 
placement to institutional shareholders by way of an accelerated 
bookbuilding. The net proceeds will be used for i) the clinical 
development of Basilea's clinical oncology drug candidates derazantinib 
and lisavanbulin, ii) pre-clinical research and development activities, 
and iii) working capital and other general corporate purposes, including 
investments in or in-licensing of complementary businesses, products or 
assets. 
 
   David Veitch, Chief Executive Officer of Basilea, said: "Through this 
transaction we have successfully expanded our institutional shareholder 
base, including leading healthcare funds, and increased our financial 
flexibility in order to create value through the progression and 
expansion of our R&D portfolio in our strategic focus areas. In 
particular, we have gained further flexibility for our most advanced 
clinical oncology assets, derazantinib and lisavanbulin, following the 
upcoming key data readouts." 
 
   Basilea placed 1 million new registered shares of CHF 1.00 par value 
each at CHF 45.75 per new share. The new shares, corresponding to 8.4% 
of Basilea's currently issued share capital, will be issued from 
Basilea's authorized share capital, excluding subscription rights of 
existing shareholders. The new shares are expected to be listed and 
admitted to trading on SIX Swiss Exchange on February 26, 2021. Payment 
and settlement are expected to take place on or around February 26, 
2021. The new shares will rank pari passu with the existing shares. 
 
   In connection with the offering, Basilea has agreed to a 150-day lock-up 
period following the settlement, subject to customary exceptions. 
Members of the Board of Directors and Management of Basilea have agreed 
to a 150-day lock-up period following the settlement, subject to 
customary exceptions. 
 
   As a result of the transaction, Basilea updates its financial guidance 
for 2021. It maintains its revenue and operating loss guidances and 
increases its guidance relating to cash and investments to approximately 
CHF 155 - 160 million at year-end 2021. 
 
   Cantor Fitzgerald, Credit Suisse and Bryan Garnier acted as Joint 
Bookrunners in connection with the offering. 
 
   About Basilea 
 
   Basilea is a commercial-stage biopharmaceutical company founded in 2000 
and headquartered in Switzerland. We are committed to discovering, 
developing and commercializing innovative drugs to meet the medical 
needs of patients with cancer and infectious diseases. We have 
successfully launched two hospital brands, Cresemba for the treatment of 
invasive fungal infections and Zevtera for the treatment of severe 
bacterial infections. We are conducting clinical studies with two 
targeted drug candidates for the treatment of a range of cancers and 
have a number of preclinical assets in both cancer and infectious 
diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange 
(SIX: BSLN). Please visit basilea.com 
https://www.globenewswire.com/Tracker?data=XatuGet1KtgmRlf1XbIWOXdjuoDhJgtIGkIjP16ut7rnVCHv2Ro7gY_7uY6HQEb1s4EcrBUuszP8jDQzY24B_w== 
. 
 
   Disclaimer 
 
   This communication constitutes neither an offer to sell nor a 
solicitation to buy securities referred to in it ("Securities") and it 
does not constitute a prospectus or a similar notice within the meaning 
of articles 35 et seqq. or 69 of the Swiss Financial Services Act. The 
offer and listing of the Securities will be made without the publication 
of a prospectus in reliance on the exemptions provided in article 36 
paragraph 1 letter a and article 38 paragraph 1 letter a of the 
Financial Services Act. 
 
   These materials shall not constitute an offer to sell or the 
solicitation of an offer to buy, nor shall there be any sale of the 
Securities in any jurisdiction in which such offer, solicitation or sale 
would be unlawful prior to registration, exemption from registration or 
qualification under the securities laws of any such jurisdiction. 
 
   In particular, these materials are not an offer of securities for sale 
in the United States. Securities may not be offered or sold in the 
United States absent registration or an exemption from registration 
under the US Securities Act of 1933. The Securities have not been and 
will not be registered. There will be no public offering of these 
Securities in the United States. 
 
   This communication does not constitute an "offer of securities to the 
public" within the meaning of Regulation 2017/1129 of the European Union 
(the "EU Prospectus Regulation") or the EU Prospectus Regulation as it 
forms part of UK domestic law by virtue of the UK European Union 
(Withdrawal) Act 2018 (the "UK Prospectus Regulation") of the Securities 
in any member state of the European Economic Area (the "EEA") or in the 
UK. Any offers of the Securities to persons in the EEA or in the UK will 
be made pursuant to exemptions under the EU Prospectus Regulation and 
the UK Prospectus Regulation from the requirement to produce a 
prospectus for offers of the Securities. 
 
   In member states of the EEA, this communication is being distributed 
only to, and is directed only at "qualified investors" within the 
meaning of Article 2(e) of the EU Prospectus Regulation ("Qualified 
Investors"). 
 
   In the United Kingdom, this communication is being distributed only to, 
and is directed only at "qualified investors" within the meaning of 
Article 2(e) of the UK Prospectus Regulation who are also (a) persons 
who have professional experience in matters relating to investments 
falling within Article 19(5) of the Financial Services and Markets Act 
2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (b) 
high net worth entities, or (c) other persons to whom it may otherwise 
lawfully be communicated, falling within Article 49(2) of the Order (all 
such persons together being referred to as "relevant persons"). 
 
   Any investment or investment activity to which this communication 
relates is available only to Qualified Investors in the EEA and to 
relevant persons in the United Kingdom and will be engaged in only with 
Qualified Investors in the EEA and with relevant persons in the United 
Kingdom. Any person who is not a Qualified Investor or a relevant person, 
as appropriate, should not act or rely on this communication or any of 
its contents. 
 
   This communication expressly or implicitly contains certain 
forward-looking statements, such as "believe", "assume", "expect", 
"forecast", "project", "may", "could", "might", "will" or similar 
expressions concerning Basilea Pharmaceutica Ltd. and its business, 
including with respect to the progress, timing and completion of 
research, development and clinical studies for product candidates. Such 
statements involve certain known and unknown risks, uncertainties and 
other factors, which could cause the actual results, financial condition, 
performance or achievements of Basilea Pharmaceutica Ltd. to be 
materially different from any future results, performance or 
achievements expressed or implied by such forward-looking statements. 
Basilea Pharmaceutica Ltd. is providing this communication as of this 
date and does not undertake to update any forward-looking statements 
contained herein as a result of new information, future events or 
otherwise. 
 
   For further information, please contact: 
 
 
 
 
  Peer Nils Schröder, PhD 
   Head of Corporate Communications & Investor Relations 
  Phone                                     [phone] 
  E-mail        [e-mail] 
                 [e-mail] 
 
 
   This press release can be downloaded from www.basilea.com. 
 
   Attachment 
 
 
   -- Press release (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/4782ddfb-578e-4307-b600-2181ac19e909

(END) Dow Jones Newswires

February 24, 2021 01:15 ET (06:15 GMT)